CHMP påpegede, at denne indikation kun omfatter essentiel hypertension, og indikationerne udgør tillægsbehandling efter mislykket monoterapi.
The CHMP pointed out that this indication is limited to essential hypertension and the positioning of the indications is add-on therapy when each monotherapy has failed.